glp-1 non-diabetic weight loss effectiveness Only a few week old (2026 jan 22) systematic review revealed that agonists have the greatest benefit for younger female patients. https://diabetesjournals.org/care/article/48/2/292/157724/Efficacy -of-GLP-1-Receptor-Agonists-on-Weight Comparative effectiveness of GLP-1 receptor

In Australia, report concerns to the TGA for safety tracking

This effect occurs in approximately 15-20% of users and usually diminishes with continued use

This is more important with long-lasting drugs like semaglutide or tirzepatide, so the medication clears out of their system

The concentration of the buffer in the pharmaceutical formulation containing cagrilintide must also be low enough to prevent it from being ejected from the device and injected into the individual (and therefore mixed with the pharmaceutical formulation containing semaglutide) , PH drops to a level where semaglutide will precipitate or form particles